A Consistent Lack of Sleep Negatively Impacts Immune Stem Cells, Increasing Risk of Inflammatory Disorders and Heart Disease

Mount Sinai study also shows catching up on sleep doesn’t reverse possible negative effects on cellular level

Mount Sinai Researchers Use Artificial Intelligence to Uncover the Cellular Origins of Alzheimer’s Disease and Other Cognitive Disorders

Deep learning models represent “an entirely new paradigm for studying dementia”

Scientists Identify Unique Breast Cancer Cells That Control Their Ability to Proliferate and Colonize the Lungs

Scientists from The Tisch Cancer Institute have uncovered a mechanism by which certain breast cancer cells regulate their own metastases, fuel dissemination from the original tumor site, and determine routes to invade distant organs such as the lungs, according to a study published in Cell Reports in September.

Valentin Fuster, MD, PhD, Receives Prestigious Award from Cardiovascular Research Foundation

Mount Sinai Heart leader will be recognized for his exceptional career achievements at the 34th annual conference.

Mount Sinai Researchers Report Encouraging Immunotherapy Option for Relapsed Myeloma Patients

Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails. Bispecific antibodies are a type of antibody that can bind to two different antigens at the same time—they are meant to enhance the immune system’s destruction of tumor cells.

New Risk Score Predicts Mortality for Atrial Fibrillation Patients Undergoing Transcatheter Aortic Valve Replacement

Mount Sinai researchers develop new risk stratification tool to optimize patient care and outcomes after TAVR

“Polypill” Reduces Cardiovascular Mortality by 33 Percent in Patients Treated After a Heart Attack

A three-drug medication known as a “polypill,” developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this patient population.

Mount Sinai Awarded $11.6 Million Grant to Launch Comprehensive Center for Surgical Innovation and Expand Mount Sinai BioDesign

In a move that has the potential to change the future of surgery, advance quality care, and bring economic growth to New York City, Mount Sinai Health System announced today the launch of the Comprehensive Center for Surgical Innovation (CCSI).

Mount Sinai Launches Large-Scale Genetic Sequencing Project with the Regeneron Genetics Center

Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai have launched a new human genome sequencing research project called the Mount Sinai Million Health Discoveries Program with the Regeneron Genetics Center (RGC), part of the industry-leading, New York-based biotechnology company Regeneron.

Prompt Recognition and Treatment Found Effective for Lung Disease in Patients Who Received New Drug for Advanced Cancer

Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open on August 11, 2022.

Mount Sinai Awarded Three-Year Grant to Explore Therapeutic Approaches to KRAS Mutant Lung Tumors

Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer® (SU2C) to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.

Mount Sinai Announces the Formation of CastleVax Inc., a Clinical-Stage Infectious Diseases Company Developing Novel Vaccines and Therapeutics, Targeting Pandemic Threats and Diseases of Unmet Medical Need

The Mount Sinai Health System has launched CastleVax, Inc. (“CastleVax”), a clinical-stage vaccine research and development company.

High-Tech Imaging Offers New Way to Detect Signs of Early Glaucoma

Mount Sinai study shows flavoprotein fluorescence could serve as new biomarker

Black Patients Found Six Times More Likely to Have Advanced Vision Loss After Glaucoma Diagnosis Than White Patients

Black patients have a dramatically higher risk of advanced vision loss after a new diagnosis of primary open angle glaucoma (POAG) when compared to white patients, according to a new study from New York Eye and Ear Infirmary of Mount Sinai (NYEE).

High Blood Viscosity Can Predict Higher Risk of Death in Hospitalized COVID-19 Patients

EMBARGOED UNTIL JULY 18, 2022, 2PM EST                  Study Title: “Association of Blood Viscosity with Mortality among Patients Hospitalized with COVID-19” Journal: Journal of the American College of Cardiology – *Embargoed until July…

Mount Sinai Receives Prestigious Honor From American Hospital Association for Advancing Diversity, Inclusion, and Equity in Patient Care

Mount Sinai Health System named winner of 2022 Carolyn Boone Lewis Equity of Care Award

Blinding Eye Disease Is Strongly Associated With Heart Disease and Stroke

Patients with a specific form of age-related macular degeneration (AMD), a leading cause of blindness in the United States, are at significant risk for cardiovascular disease and stroke, according to new research from New York Eye and Ear Infirmary of Mount Sinai.

Blacks Found Twice as Likely to Have Atherosclerosis as Hispanics in Young Adult Populations in Underserved Communities

A unique Mount Sinai study focused on a multi-ethnic, underserved community in New York City shows that young Black adults are twice as likely to have atherosclerosis as similarly situated young Hispanic adults.

Stress Testing Can Help Determine Which Patients Are Likely to Benefit From Heart Procedures to Improve Survival

Mount Sinai study can help guide proper treatment course for patients depending on heart function and severity of heart damage

Prenatal Exposure to Chemicals in Consumer and Industrial Products Is Associated With Rising Liver Disease in Children

The growing incidence of a potentially cancer-causing liver disease in children is associated with prenatal exposure to several endocrine-disrupting chemicals, Mount Sinai researchers report.

Immune Molecules From a Llama Could Provide Protection Against a Vast Array of SARS-like Viruses Including COVID-19, Researchers Say

Mount Sinai-led researchers have shown that tiny, robust immune particles derived from the blood of a llama could provide strong protection against every COVID-19 variant, including Omicron, and 18 similar viruses.

Study Finds Untreated Sleep Apnea May Increase Risk for Neurodegenerative Disease, PAP Therapies Crucial in Treating the Sleep Condition

Mount Sinai researchers have conducted one of the first studies to show the acute effect of obstructive sleep apnea on Alzheimer’s disease biomarkers, and the ability to even measure Alzheimer’s disease biomarkers from blood.

Specific Environmental Exposures may Help Predict Increased Risk of Death from Cardiovascular Disease

A new study from the Icahn School of Medicine at Mount Sinai quantifies the cardiovascular risk posed by exposure to specific environmental factors, showing, for example, that air pollution heightens the risk of heart disease mortality by 17 percent.

Mount Sinai Researchers Develop Machine Learning Model that Can Detect and Predict COVID-19 from Collected Data on Wearable Devices

Mount Sinai researchers have developed a machine learning algorithm that can determine if an individual has SARS-CoV-2 infections, the virus that causes COVID-19—with a high sensitivity and specificity—from the data collected by wearable devices.

Mount Sinai Researcher Receives Prestigious Award From the American Association of Indian Scientists in Cancer Research

Nina Bhardwaj, MD, PhD, Director of Immunotherapy at The Tisch Cancer Institute at Mount Sinai, has received the 2022 Lifetime Achievement in Cancer Research award from the American Association of Indian Scientists in Cancer Research (AAISCR).

Heart Failure Patients Unvaccinated Against COVID-19 Are Three Times More Likely to Die From It Than Boosted Heart Failure Patients

EMBARGOED UNTIL JUNE 9, 2022, 10AM EST (New York, NY – June 9, 2022) – Heart failure patients who are unvaccinated against SARS-CoV-2, the virus that causes COVID-19, are three times more likely to die if infected with the virus…

Biomarker in Liquid Biopsy for Lung Cancer Appears More Accurate in Predicting Immunotherapy Response Than Tumor Biopsy

Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure. Their study was published in the Journal of Experimental & Clinical Cancer Research in June.

The Mount Sinai Hospital Recognized on Newsweek’s “America’s Best Maternity Hospitals 2022” List

The Mount Sinai Hospital has earned top honors on Newsweek’s list of “America’s Best Maternity Hospitals 2022” for providing high-quality maternity care from pregnancy through birth, as well as postpartum care to ensure the long-term health of both newborns and new mothers.

Mount Sinai Receives Landmark Gift from Royalty Pharma to Advance Health Equity

Marking a major advance in its efforts to achieve equity in the delivery of health care, the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) announced today that its Institute for Health Equity Research (IHER) has received a landmark $20 million gift over five years from Royalty Pharma plc (Nasdaq: RPRX) and certain members of its management team.

Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates

Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results presented at the American Urological Association (AUA) annual meeting in May.

Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai Announce a Joint Center for Engineering and Precision Medicine in New York City

Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai today announced the creation of the Center for Engineering and Precision Medicine (CEPM), one of the first centers in the nation to bridge engineering and engineering science with medicine. This undertaking will build on a wealth of shared basic research discoveries, explore unique therapeutic innovations in cancer, Alzheimer’s and a myriad of infectious diseases; educate a new generation of biomedical leaders; and develop new technologies and processes that enhance patient outcomes in unprecedented ways. CEPM represents an evolution in the successful partnership between Mount Sinai and RPI, one that has secured over $70 million in shared research funding since 2013 with 90 percent of that provided by the National Institutes of Health.

Neighborhoods Most Affected by Racism, Inequities and COVID-19 Pandemic Stressors at a Greater Risk for Preterm Births, Study Finds

The cohort study follows women through pregnancy and birth to study if a SARS-CoV-2 infection, the virus that causes COVID-19, is associated with poor pregnancy outcomes.

Mount Sinai’s Brendan Carr, MD, MS, Receives Prestigious “Chair of the Year Award” from Emergency Medicine Residents’ Association

The Emergency Medicine Residents’ Association (EMRA) of the American College of Emergency Physicians has honored Brendan G. Carr, MD, MS, Chair of Emergency Medicine at the Icahn School of Medicine of Mount Sinai and Mount Sinai Health System, with the prestigious “2022 Chair of the Year Award.” He is the only department chair in the country to receive this distinction for 2022, recognizing his exceptional leadership.

Mount Sinai Cardiologist Develops New Risk Score to Help Predict Possible Contrast-Associated Kidney Injury After Percutaneous Coronary Intervention

Assessment can help stratify high-risk patients for monitoring before, during, and after procedures to improve outcomes

Novel Surgical Device Can Potentially Improve Outcomes of Coronary Bypass Grafting That Uses Leg Veins

(New York, NY – November 13, 2021) –A novel device called venous external support (VEST) may lead to increased longevity and durability of saphenous (leg) vein grafting during coronary artery bypass surgery, according to a new trial done in collaboration…

New Treatment Approach for Advanced Coronary Artery Disease Leads to Improved Outcomes

Study outlines better way to identify where stents are necessary

Renowned Physician-Scientist with Expertise in High-Risk Pregnancies Named System Chair of Obstetrics, Gynecology, and Reproductive Science at Mount Sinai Health System

Joanne L. Stone, MD, a leading physician-scientist in women’s health with special expertise in fetal imaging and caring for high-risk pregnancies, has been named the Chair of Obstetrics, Gynecology, and Reproductive Science for the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System. Dr. Stone currently serves as Director of the Maternal-Fetal Medicine and Fellowship program for the Mount Sinai Health System, Vice Chair for Diversity and Inclusion of the OB/GYN Department, and Immediate Past President of the Faculty Council.

32BJ Health Fund, In Partnership With Mount Sinai Health System, Announces First-In-The-Nation Regional Centers of Excellence

The 32BJ Health Fund and the Mount Sinai Health System today announced expansion of their unique Centers of Excellence program, which provides bariatric and joint replacement surgeries at no-cost to Fund participants, to include partner hospitals in New Jersey, Connecticut, Florida, Massachusetts, and Pennsylvania.